Images — Isolated forearm soft tissue metastasis from bladder cancer

Cameron Gregory Ashe¹; Scott Bagnell, MD²; Samantha Gray, MD³

¹MD candidate, Dalhousie University Faculty of Medicine, St. John, NB, Canada; ²Department of Urology, Dalhousie University, Saint John Regional Hospital, St. John, NB, Canada; ³Department of Oncology, Dalhousie University, Saint John Regional Hospital, St. John, NB, Canada


Published online August 30, 2018

Introduction

Bladder cancer is the ninth most prevalent cancer in the world and most common malignancy involving the urinary system, with 430 000 cases diagnosed in 2012.¹ Urothelial cell carcinoma (UCC, also known as transitional cell carcinoma) is considered to be the predominant histological type of bladder cancer in the U.S. and Western Europe. While greater than 50% of UCC cases are non-muscle-invasive with relatively good prognosis, soft tissue invasion and metastatic spread offer much worse outcomes.² The most common areas for metastatic spread of UCC are the lymph nodes, bones, lung, and liver. Advanced UCC has a poor prognosis, with an overall five-year survival of less than 15%.³

Recent reports of the distribution of UCC metastases from clinical sites found evidence of soft tissue metastases, however, these occurred in the presence of advanced stage disease with lesions present in additional locations of the body.⁴ ⁵ UCC metastases to soft tissue in the absence of disease elsewhere in the body are exceedingly rare and few cases are described.

We present the rare case of a 70-year-old patient with metastases to the soft tissue of the arm without other sites of recurrence, six months after radical cystoprostatectomy for muscle-invasive UCC of the bladder.

Case report

A 70-year-old male presented to his general practitioner with gross hematuria. He underwent abdominal imaging, which showed a 6 cm exophytic bladder mass. Subsequent cystoscopy and transurethral resection of the bladder (TURB) confirmed a high-grade urothelial cancer with muscle invasion.

He underwent four cycles of cisplatin-based neoadjuvant chemotherapy (delivered by peripherally inserted central catheter (PICC) in the right arm), followed by radical cystoprostatectomy. The final pathology confirmed a ypT2bN0 high-grade UCC.

Subsequent imaging performed three months postoperatively demonstrated no evidence of local recurrence or metastatic disease.

The patient then presented to his family physician with left arm swelling five months postoperatively. Given the patient was on anticoagulation, and had a history of mild trauma, it was initially felt to be a hematoma, but magnetic resonance imaging (MRI) was ordered to investigate.

The MRI of the arm (Fig. 1) found a soft tissue mass 3.0x2.2x1.5 cm in size. It was thought that this would be a very unusual metastasis from a primary bladder cancer and so the clinical opinion was suspicious of a sarcoma. A computed tomography (CT) of the chest, abdomen, and pelvis with enhancement done at the same time showed no evidence of metastatic disease from the bladder cancer.

The patient underwent an open biopsy, which revealed a neoplastic infiltrate within the connective tissue stroma with foci of lymphovascular invasion (Fig. 2). The malignant cells were similar in appearance to those noted in the patient’s previous cystectomy specimen. Immunostaining supported the histological interpretation of metastatic urothelial carcinoma.

A subsequent positron emission tomography (PET) scan was arranged and no evidence of metastatic disease was found beyond the known left forearm lesion.

After discussion at multidisciplinary rounds, the patient was referred for consideration of stereotactic body radiation therapy (SBRT) to the forearm metastasis. Unfortunately, given the proximity to skin, it was not recommended, and as such, palliative high-dose radiation was arranged to the left forearm.

Two months subsequent to the radiation therapy, the mass persisted, with no real regression in the size of the mass, although there was noted to be central necrosis and edema, likely radiation-induced. Given no progression outside of the arm, after multidisciplinary consultation and discussion with the patient, the decision was made to pursue a more aggressive approach, and the patient underwent an attempted local excision of the tumour. However, damage to the tumour area...
Discussion

Soft tissue metastases from a distant primary lesion are rare in most cancers, even with the large amount of soft tissue in the body. In the context of UCC, soft tissue metastases appear to be even more rare, with recent reviews finding few cases of soft tissue metastases. In addition, the metastases were found in instances of advanced stage cancer. Only one case study was found that also showed an isolated metastasis from UCC of the bladder to the sartorius muscle. To our knowledge, there has been no other UCC soft tissue metastases that has occurred in the presence of negative imaging studies, which demonstrate no other disease recurrence.

Most cases in the literature presented with localized and painful muscular swelling in a similar manner to our patient. Interestingly, as occurred in our patient, local trauma has been reported to be a potential risk factor for development of metastases. It is hypothesized that injury may in some way alter the physiology and microenvironment at the site of trauma and therefore result in increased susceptibility to the development of metastatic disease at that site of trauma.

The treatment for soft tissue metastases is unclear, and generally is palliative, given most patients present in the context of advanced disease. Given the poor prognosis associated with metastatic bladder cancer, it is unknown whether aggressive treatment to an isolated metastasis is warranted. Past case studies of isolated metastases to soft tissue have been treated aggressively with a variable combination of bloc excision, radiation, and chemotherapy.9,10

Our patient will be followed closely for regular oncological surveillance for recurrent metastatic disease.

Competing interests: Dr. Bagnell has been a speaker for AstraZeneca, GSK, and Pfizer. Dr. Gray has participated in advisory boards for Amgen, Astellas, and Sanofi; and has participated in clinical trials supported by Amgen, Aragen Pharmaceuticals, and DaichiSanyko. Mr. Ashe reports no competing personal or financial interest related to this work.

This paper has been peer-reviewed.

References


Correspondence: Mr. Cameron Gregory Ashe, Dalhousie University Faculty of Medicine, St. John, NB, Canada; cameron.ashe@dal.ca